ReNeuron Group Plc (RENE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ReNeuron Group Plc (RENE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10128
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ReNeuron Group Plc (ReNeuron) is a clinical-stage stem cell company which develops innovative stem cell therapies targeting areas of significant unmet medical need. The company’s therapeutic candidates in clinical development are focused at treating motor disability as a result of stroke, critical limb ischaemia and the blindness-causing disease retinitis pigmentosa. Its lead CTX stem cell therapeutic candidate is a therapy for treating patients left disabled by a stroke. ReNeuron utilizes its exclusive stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be administered “off-the-shelf” to any fit patient without the requirement for additional immunosuppressive drug treatments. ReNeuron is headquartered in Pencoed, Bridgend, the UK.

ReNeuron Group Plc (RENE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReNeuron Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ReNeuron Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
ReNeuron Enters into Research Agreement with Benitec Biopharma 12
ReNeuron Enters Into Co-Development Agreement With Cell Therapy Catapult 13
Licensing Agreements 14
ReNeuron Enters into Licensing Agreement with US-Based Pharma Company 14
Equity Offering 15
ReNeuron Raises USD105 Million in Private Placement of Shares 15
ReNeuron Raises USD25.4 Million in Private Placement of Shares 16
ReNeuron Group Completes Private Placement Of Shares For US$8.7 Million 17
ReNeuron Group Completes Rights Offering Of Shares For US$1 Million 19
ReNeuron Group Plc – Key Competitors 21
ReNeuron Group Plc – Key Employees 22
ReNeuron Group Plc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Jul 12, 2018: ReNeuron: Preliminary results for the year ended 31 March 2018 24
Dec 14, 2017: ReNeuron Group: Interim Results for the six months ended 30 September 2017 30
Jun 29, 2017: ReNeuron Group: Preliminary Results for the Year Ended 31 March 2017 33
Corporate Communications 34
Apr 10, 2018: ReNeuron: Appointment of US-based Chief Medical Officer 34
Apr 10, 2018: Appointment Of US-Based Chief Medical Officer 35
Sep 01, 2017: ReNeuron Group: Non-executive Director Appointment 36
Jul 19, 2017: ReNeuron Group: Board change 37
Government and Public Interest 38
Apr 19, 2018: ReNeuron: Wins grant for retinal cell therapy development 38
May 11, 2017: ReNeuron awarded major UK cell therapy manufacturing grant 39
Jan 23, 2017: Merck Announces Emerging Biotech Grant Program Winners 40
Product News 41
11/08/2017: ReNeuron Group: Retinal disease clinical trial moves into Phase II 41
06/19/2017: FDA approves cryopreserved formulation of ReNeurons retinal stem cell therapy candidate 42
05/05/2017: ReNeuron presents new data with its exosome therapy programme at major scientific conference 43
04/19/2018: ReNeuron wins grant for retinal cell therapy development 44
Mar 26, 2018: ReNeuron Group: Product Development Update 45
Clinical Trials 47
May 04, 2018: ReNeuron Group: Exosome data presented at ISCT conference 47
Feb 13, 2018: ReNeuron Group: Positive pre-clinical data in nerve injury 48
Jan 26, 2018: ReNeuron: Phase II stroke data presented at AHA conference 49
Dec 14, 2017: ReNeuron Group: Stroke Clinical Trial Regulatory Approval in US 50
Oct 31, 2017: ReNeuron Group: Positive stroke clinical data & regulatory update 51
Oct 09, 2017: ReNeuron presents positive pre-clinical data with its ExoPr0 exosome cancer therapy candidate at American Society for Exosomes and Microvesicles 2017 Annual Meeting 52
Jun 05, 2017: ReNeuron progresses clinical and regulatory strategy for the US with stroke programme based on positive FDA regulatory feedback 53
May 18, 2017: ReNeuron presents positive pre-clinical data with its ExoPr0 exosome therapy candidate at major scientific conference 54
Apr 21, 2017: ReNeuron advances global clinical development strategy with cell therapy candidate for stroke disability 55
Other Significant Developments 56
Sep 19, 2018: ReNeuron Group provides business development update 56
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 57
Apr 21, 2017: ReNeuron successfully develops cryopreserved formulation of its retinal stem cell therapy candidate and expands ophthalmology programmes 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReNeuron Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReNeuron Group Plc, Deals By Therapy Area, 2012 to YTD 2018 9
ReNeuron Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ReNeuron Enters into Research Agreement with Benitec Biopharma 12
ReNeuron Enters Into Co-Development Agreement With Cell Therapy Catapult 13
ReNeuron Enters into Licensing Agreement with US-Based Pharma Company 14
ReNeuron Raises USD105 Million in Private Placement of Shares 15
ReNeuron Raises USD25.4 Million in Private Placement of Shares 16
ReNeuron Group Completes Private Placement Of Shares For US$8.7 Million 17
ReNeuron Group Completes Rights Offering Of Shares For US$1 Million 19
ReNeuron Group Plc, Key Competitors 21
ReNeuron Group Plc, Key Employees 22
ReNeuron Group Plc, Subsidiaries 23

List of Figures
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ReNeuron Group Plc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[ReNeuron Group Plc (RENE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Qatari Diar Real Estate Investment Co:企業のM&A・事業提携・投資動向
    Qatari Diar Real Estate Investment Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Qatari Diar Real Estate Investment Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed report …
  • China Sunergy Co., Ltd.:企業の戦略的SWOT分析
    China Sunergy Co., Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • University of California San Diego:医療機器:M&Aディール及び事業提携情報
    Summary University of California San Diego (UCSD), a subsidiary of University of California, is a public research university that offers education and research with a portfolio of undergraduate, graduate, postdoctoral and professional schools. It offers courses in various fields including arts and h …
  • Energias de Portugal SA (EDP):電力:M&Aディール及び事業提携情報
    Summary Energias de Portugal, S.A. (EDP) is a vertically integrated power and gas utility that generates, transmits, distributes and sells electricity; and transports, distributes and sells natural gas. It produces electricity through a diversified portfolio of generation assets including wind, sola …
  • Emami Limited:戦略・SWOT・企業財務分析
    Emami Limited - Strategy, SWOT and Corporate Finance Report Summary Emami Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Five Prime Therapeutics Inc (FPRX):企業の財務・戦略的SWOT分析
    Five Prime Therapeutics Inc (FPRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Sysco Corporation:企業の戦略・SWOT・財務情報
    Sysco Corporation - Strategy, SWOT and Corporate Finance Report Summary Sysco Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • JK Sucralose Inc.:企業の戦略・SWOT・財務情報
    JK Sucralose Inc. - Strategy, SWOT and Corporate Finance Report Summary JK Sucralose Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Rex International Holding Ltd (5WH):企業の財務・戦略的SWOT分析
    Summary Rex International Holding Ltd (Rex International) formerly Rex International Holding Pte Ltd is an independent exploration and production oil company. The company develops oil and gas properties across Singapore. It operates substantial oil and gas exploration concessions in the UAE, Oman, N …
  • SNC-Lavalin Group Inc.:企業の戦略・SWOT・財務分析
    SNC-Lavalin Group Inc. - Strategy, SWOT and Corporate Finance Report Summary SNC-Lavalin Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Altana AG:企業の戦略的SWOT分析
    Altana AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Bank Of The Philippine Islands:企業の戦略・SWOT・財務分析
    Bank Of The Philippine Islands - Strategy, SWOT and Corporate Finance Report Summary Bank Of The Philippine Islands - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • PanAtlantic Exploration Co:企業の戦略的SWOT分析
    PanAtlantic Exploration Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Bellicum Pharmaceuticals Inc (BLCM):企業の財務・戦略的SWOT分析
    Summary Bellicum Pharmaceuticals, Inc. (Bellicum) is a clinical stage biopharmaceutical company, which is engaged in developing cellular immunotherapies for the treatment of cancer. The company develops its product candidates through its chemical induction of dimerization technology platforms in the …
  • Rotork Plc (ROR):石油・ガス:M&Aディール及び事業提携情報
    Summary Rotork Plc (Rotork) is a manufacturer of actuator. The company’s key offerings include electric actuators, fluid power actuators, gearboxes, mounting kits and precision control instruments. The company also provides installation, maintenance and repair, field services, technical support and …
  • Grainger Plc (GRI):企業の財務・戦略的SWOT分析
    Grainger Plc (GRI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Qioptiq Group:企業の戦略的SWOT分析
    Qioptiq Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • TransMontaigne Partners LP (TLP):企業の財務・戦略的SWOT分析
    Summary TransMontaigne Partners LP (TLP), a subsidiary of TransMontaigne GP LLC is an energy infrastructure service provider that offers integrated terminaling, transportation, and storage services. The company distributes and transports crude oil, chemicals, petroleum products, fertilizers, and oth …
  • Parex Resources Inc (PXT):石油・ガス:M&Aディール及び事業提携情報
    Summary Parex Resources Inc (Parex) is an oil and gas exploration and development company that acquires, explores, develops and produces crude oil and natural gas in South America and the Caribbean. The company holds interests in land base of 1.7 million gross acres over 22 blocks in Colombia's Llan …
  • Intarcia Therapeutics Inc-医療機器分野:企業M&A・提携分析
    Summary Intarcia Therapeutics Inc (Intarcia), formerly BioMedicines Inc, is a biopharmaceutical company that discovers, develops and commercializes drug therapies to reduce effects for chronic diseases. The company’s product candidate include ITCA 650, which is in Phase III clinical trial. Its ITCA …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆